GBA Group has acquired KaLy-Cell SAS, expanding its European pharmaceutical network in France.
The acquisition, which was announced and closed on September 5, 2022, sees GBA Group acquiring a 100% stake in KaLy-Cell. Financial terms of the deal were not disclosed. Neither side revealed their financial or legal advisors.
Deal Mechanics
KaLy-Cell SAS was established as a spin-off from the University of Bourgogne Franche-Comté in 2003 and is headquartered in Plobsheim, France. The company offers contract research services with hepatocytes from various species to optimize drug discovery, development, and approval for medicines, food additives, and agrochemicals.
By acquiring KaLy-Cell, GBA Group aims to strengthen its presence in the European pharmaceutical market, particularly in France, where it can now offer a comprehensive portfolio of services across the stages of new drug development and chemical product applications.
Strategic Rationale
The acquisition supports GBA Group's strategy to expand its service offerings within the European pharma network. With this move, GBA Group enhances its capability to serve both national and international clients with a broader array of services spanning various phases of pharmaceutical development.
Financial Context
KaLy-Cell SAS is known for its contributions to relevant safety studies and enjoys an excellent reputation within the industry due to its reputable client base. The acquisition aims to bolster GBA Group’s operational footprint in France, aligning with their broader goals of market expansion.
Advisors
No financial or legal advisors were disclosed for either side of the transaction.
Outlook
This acquisition marks a significant step towards consolidating GBA Group's position in the European pharmaceutical sector. It is expected to enhance the company’s service portfolio, enabling greater collaboration with existing and potential clients across different geographical markets.